426 related articles for article (PubMed ID: 30153975)
1. Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.
Petrioli R; Francini E; Cherri S; Torre P; Fiaschi AI; Miano ST; Marrelli D; Rovello F; Francini G
Clin Colorectal Cancer; 2018 Dec; 17(4):e663-e669. PubMed ID: 30153975
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
3. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Souglakos J; Kalykaki A; Vamvakas L; Androulakis N; Kalbakis K; Agelaki S; Vardakis N; Tzardi M; Kotsakis AP; Gioulbasanis J; Tsetis D; Sfakiotaki G; Chatzidaki D; Mavroudis D; Georgoulias V
Ann Oncol; 2007 Feb; 18(2):305-10. PubMed ID: 17079693
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial).
Kosugi C; Koda K; Denda T; Ishibashi K; Ishida H; Seike K; Sakata H; Yanagisawa S; Miyazaki A; Takayama W; Koike N; Shimizu H; Matsubara H
Int J Colorectal Dis; 2021 Dec; 36(12):2637-2647. PubMed ID: 34368890
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).
Nakayama G; Ishigure K; Yokoyama H; Uehara K; Kojima H; Ishiyama A; Hayashi N; Takano N; Hattori N; Kobayashi D; Tanaka C; Hayashi M; Kanda M; Yamada S; Sugimoto H; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
BMC Cancer; 2017 Apr; 17(1):243. PubMed ID: 28376737
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U
Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.
Munemoto Y; Kanda M; Ishibashi K; Hata T; Kobayashi M; Hasegawa J; Fukunaga M; Takagane A; Otsuji T; Miyake Y; Nagase M; Sakamoto J; Matsuoka M; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():786. PubMed ID: 26497654
[TBL] [Abstract][Full Text] [Related]
9. Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial.
Matsui T; Nagata N; Hirata K; Okazaki S; Sato S; Nakamura M; Kim H; Oba K; Sakamoto J; Mishima H
Anticancer Res; 2016 Jul; 36(7):3437-43. PubMed ID: 27354605
[TBL] [Abstract][Full Text] [Related]
10. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas.
Alifieris CE; Griniatsos J; Delis SG; Nikolaou M; Avgoustou C; Panagiotidis MI; Souferi-Chronopoulou E; Trafalis DT
Am J Clin Oncol; 2020 May; 43(5):305-310. PubMed ID: 32343515
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.
Hagman H; Frödin JE; Berglund Å; Sundberg J; Vestermark LW; Albertsson M; Fernebro E; Johnsson A
Ann Oncol; 2016 Jan; 27(1):140-7. PubMed ID: 26483047
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
Suzuki N; Hazama S; Nagasaka T; Tanioka H; Iwamoto Y; Negoro Y; Yamauchi M; Kobayashi M; Okuda H; Fujishima N; Nishimura T; Yamanaka N; Toyota K; Mori Y; Nakagami Y; Shimokawa M; Nagano H; Okajima M
Int J Clin Oncol; 2019 Oct; 24(10):1223-1230. PubMed ID: 31144145
[TBL] [Abstract][Full Text] [Related]
16. Practical use of capecitabine plus oxaliplatin (CAPEOX) with bevacizumab for patients with metastatic colorectal cancer that cannot expect conversion therapy.
Yokomizo H; Yoshimatsu K; Otani T; Osawa G; Nakayama M; Matsumoto A; Yano Y; Okayama S; Naritaka Y
Hepatogastroenterology; 2013; 60(128):1911-5. PubMed ID: 24719926
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women.
Su J; Lai J; Yang R; Xu B; Zhu Y; Zhao M; Yang C; Liang G
BMC Gastroenterol; 2019 Jan; 19(1):17. PubMed ID: 30683047
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients.
Ozcelik M; Odabas H; Ercelep O; Yuksel S; Mert AG; Aydin D; Surmeli H; Isik D; Isik S; Oyman A; Oven Ustaalioglu BB; Aliustaoglu M; Gumus M
Clin Transl Oncol; 2016 Jun; 18(6):617-24. PubMed ID: 26459249
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Cunningham D; Lang I; Marcuello E; Lorusso V; Ocvirk J; Shin DB; Jonker D; Osborne S; Andre N; Waterkamp D; Saunders MP;
Lancet Oncol; 2013 Oct; 14(11):1077-1085. PubMed ID: 24028813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
